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S206 Poster Session Iand efficacy of P 1 G in pts with GCT who had previously failed
collection.
This is a retrospective analysis of pts withGCT enrolled in theUS
plerixafor compassionate use program. In this trial, pts with previous
mobilization failure (defined as the inability to collect $ 2x106
CD341 cells/kg or to achieve an adequate peripheral blood (PB)
count), were remobilized with P1G. G (10mg/kg SC) was given ev-
ery morning for 5 days. P (0.24 mg/kg SC) was given in the evening
onDay 4,11 hours prior to apheresis the next day. P, G, and apher-
esis were repeated until pts collected $ 2x106 CD341 cells/kg.
Records of 21 males with GCTwere analyzed. Median age was 35
years. Previous mobilization regimens included growth factor (GF)
alone in 14 (67%) and GF 1 chemotherapy in 7 (33%) pts; 17
(81%) pts failed to collect theminimum transplantable cell dose (me-
dian yield: 1.35 (range, 0.33 - 2.1) x106 CD341 cells/kg); 4 (19%) pts
did not undergo apheresis due to low PB CD341 cells. Remobiliza-
tion with P1 G resulted in a median yield of 3.2x106 CD341 cells/
kg. Seventeen (81%) pts collected$ 2x106 and 9 (43%) pts collected
$ 4x106 CD341 cells/kg in a median of 2 (range 1-3) and 3 (range 1-
4) days, respectively. Sixteen (76%) pts proceeded to transplant; 8
(38%) pts received tandem transplants. Median times to neutrophil
and platelet engraftment were 11 and 21 days, for single transplant
and 10.5 and 24 days, for tandem transplants. Drug-related adverse
events were observed in 8 (38%) pts; most were mild and commonly
included diarrhea (n 5 3), nausea (n 5 2), injection site reactions
(n 5 2), chills (n 5 2) and bone pain (n 5 2). There were no serious
adverse events.
The majority of pts with GCT who had failed prior mobilization
with GF6 chemotherapy could collect an adequate number of HSC
with P 1 G for at least 1 transplant. Using this approach 76% and
38% of pts could undergo a single and tandem transplant respec-
tively. None of these pts would have collected sufficient cells to
proceed to transplant without this approach.
Table 1. Remobilization OutcomesNo. of Patients 21Median age (range) 35 (20-51)Gender, male (%) 21 (100)Median CD34+ cells/kg  106 Collected (range) 3.2 (0.76 - 15.80)
No. of patients collecting$2  106 CD34+ cells/kg (%) 17 (81)
No. of patients collecting$4  106 CD34+ cells/kg (%) 9 (43)
Median days to collect$2 106 CD34+ cells/kg (range) 2 (1-3)
Median days to collect$4 106 CD34+ cells/kg (range) 3 (1-4)
No. of patients proceeding to single transplant (%) 16 (76patients proceeding
to single transplant (%))No. of patients proceeding to tandem transplant (%) 8 (38)Median days to neutrophil engraftment (range) 11 (9-18)*Median days to platelet engraftment (range) 20 (12-48)**No significant differences were seen in engraftment times between the
first and second transplant142
BUMELTT (BUSULPHAN, MELPHALAN, AND THIOTEPA) AS A PREPARA-
TIVE REGIMEN PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION
IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN’S DISEASE DOES
NOT OFFER ANY ADVANTAGE OVER MORE STANDARD REGIMENS LIKE
BEAM OR BEAC
Ganguly, S.1, Jain, V.2, Divine, C.L.1, Ajitawi, O.1, Abhyankar, S.1,
McGuirk, J.P.1 1University of Kansas Center, Kansas City, KS; 2Univer-
sity of Kansas Medical Center, Kansas City, KS
High-dose chemotherapy with carmustine, etoposide, cytosine ara-
binoside, and melphalan (BEAM) or cyclophosphamide (BEAC) fol-
lowed by autologous hematopoietic stem cell transplantation (ASCT)
represents a standard therapy for many patients with relapsed Hodg-
kin’s disease (HD). Amore intense preparative regimen like BuMelTT
(busulphan, melphalan, and thiotepa) has been applied in patients with
hematological malignancies with variable success and toxicity.
In an attempt to compare efficacy, outcome, and toxicity of
BuMelTT versus more standard BEAM or BEAC in patients with
HDundergoing ASCT, we retrospectively evaluated our center’s ex-
perience between January 2008 and April 2010.Out of 9 patients in the BuMelTT group (median age 30y; range
19-46y), 8 patients (89%) had active disease and out of 14 patients in
the BEAM (n 5 11)/ BEAC (n 5 3) group (median age 33y; range
20-67y), 10 patients (72%) had active disease at the time of transplan-
tation. The probability of disease-free survival (DFS) (55% in
BuMelTT versus 43% in BEAM/BEAC group; p5 0.6) and overall
survival (OS) (83% in BuMelTT versus 85% in BEAM/BEAC
group; p 5 0.4) were comparable in both the groups at one year
with a median duration of follow-up of 17 months. Probability of
DFS (BuMelTT 43%; BEAM/BEAC 18%; p 5 0.5) and OS
(BuMelTT 83%; BEAM/BEAC 85%; p 5 0.9) at one year when
transplanted with active disease were comparable between the two
groups as well. No patient died from transplant-related complica-
tions.More patients in the BuMelTTgroup (100%) developed grade
2 or greater mucositis compared to patients in the BEAM/BEAC
group (50%). Average length of stay was longer in BuMelTT group
(median 21 days; range 18-22) compared to BEAM/BEAC group
(median 18 days; range 9-36) (p 5 0.016) with more observed inpa-
tient cost with BuMelTT (mean: $51,650; range $33,242-166,867
versus $40,730; range $22, 661-63,668) (p 5 0.03).
In conclusion, BuMelTT as a preparative regimen was not supe-
rior compared tomore standard BEAMor BEAC in patients with re-
lapsed/refractory HD. BuMelTT chemotherapy is associated with
more GI toxicity, longer hospital stay and greater observed cost.143
MEASUREMENT OF ALDEHYDE DEHYDROGENASE ACTIVITY IN
ALLOGENEIC OR AUTOLOGOUS PERIPHERAL STEMCELL GRAFTS MAY
SUBSTITUTE TIME CONSUMING CELLS CULTURES
Leitner, G.C.1, Bartuschka, A.1, Schulenburg, A.2 1TransfusionMedicine,
Vienna, Austria; 2BMT Unit, Vienna, Austria
Background: Autologous and allogeneic stem cell (PBSC) trans-
plantations are a curative option in hematologic-oncologic diseases.
In daily routine stem cell harvests are measured on CD34 antigen
and vitality. The colony-forming ability (CFU) of the harvested stem
cells is predictive for the hematological engraftment but results are
not available until 14 days. Themetabolic marker aldehyde dehydro-
genase (ALDH) was found in hematological vital stem cells. Former
investigations described a correlation between ALDH activity of
harvested stem cells and CFU. Therefore this assay may be useful
for characterizing PBSC graft quality, especially as the results are
available simultaneously to the CD34 and vitality data.
In a prospective analysis we investigated the ALDH activity in
freshly collected PBSC and in frozen products and correlated the re-
sults with the number of CFUs
Material and Methods: In the allogeneic setting 16 PBSC harvests
from 13 donors, 7 males and 6 females, median age of 45 years (24-
60) and in the autologous setting 42 products of 25 patients, 15males
and 10 females, median age 52 years (21-67) were investigated.
Stem cell harvests were measured on CD341 cells and vitality
with 7 AAD by flow cytometry according to the ISHAGE protocol.
ALDH activity was also determined by FACS analysis using the Al-
deflourkit (Stemcell Technologies, France) according to the man-
ufacture’s instructions.
Analyses were done in freshly collected PBSCs and in cryopre-
served products before transplantation or after 6 months of storage,
respectively.
Results:The allogeneic stem cell grafts had a CD34 purity of 0.74%
(0.47-1.83), an ALDH activity of 0.7% (0.45-2.18) and a CFU con-
tent of 236  105 (28-480).
The autologous grafts showed aCD34purityof 0.6% (0.11-7.63), an
ALDH activity of 0.59% (0.15-8.89) and CFUs of 139 105 (0-892).
CFUs and ALDH activity showed a higher correlation than CFUs
and CD341 cells in the autologous grafts (R0.73 vs R0.40) No such
difference was observed in the allogeneic grafts. Low initial ALDH
activity (below 0.20%) was combined with low numbers and low
recovery of CFUs after thawing frozen PBSC. No correlation was
observed between vitality and CFUs in both settings.
Conclusion: Measuring of ALDH activity in PBSCs may alleviate
the PBSC harvest management in patients with CD34 yields near
the threshold for a successful transplantation.
